BrightView Holdings BV 深 滬
等待開盤 01-29 09:30:00 美东时间
13.12
-0.060
-0.46%
華盛通- 最 高13.21
- 今 開13.16
- 成交量 41.78万股
- 最 低 13.03
- 昨 收 13.18
- 總市值 12.42亿
- 52周最高 17.105
- 市盈率 靜 98.94
- 換手率 0.44%
- 52周最低 11.06
- 委 比 75.82%
- 總股本 9470.00万
- 歷史最高 23.42
- 量 比 0.83
- 振 幅 1.37%
- 歷史最低 2.82
- 每 手 1
- 風險率 1.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Morgan Stanley Maintains Equal-Weight on BrightView Hldgs, Raises Price Target to $13
Morgan Stanley analyst Toni Kaplan maintains BrightView Hldgs (NYSE:BV) with a Equal-Weight and raises the price target from $12 to $13.
2025-12-17 22:11
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Baird Maintains Outperform on BrightView Hldgs, Lowers Price Target to $15
Baird analyst Andrew Wittmann maintains BrightView Hldgs (NYSE:BV) with a Outperform and lowers the price target from $19 to $15.
2025-11-20 22:09
BrightView Hldgs Sees FY2026 Sales $2.670B-$2.730B vs $2.690B Est
BrightView Hldgs (NYSE:BV) sees FY2026 sales of $2.670 billion-$2.730 billion vs $2.690 billion analyst estimate.
2025-11-20 05:12
BrightView Hldgs Q4 Adj. EPS $0.27 Misses $0.32 Estimate, Sales $702.800M Miss $718.574M Estimate
BrightView Hldgs (NYSE:BV) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.32 by 14.83 percent. This is a 10 percent decrease over earnings of $0.30 per share from the
2025-11-20 05:11
BrightView Hldgs Affirms FY2025 Sales Guidance of $2.680B-$2.730B vs $2.737B Est
BrightView Hldgs (NYSE:BV) affirms FY2025 sales outlook from $2.680 billion-$2.730 billion to $2.680 billion-$2.730 billion vs $2.737 billion estimate.
2025-08-07 04:18
